Peptic ulcer pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
(11 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
A major causative factor (60% of [[gastric]] and 90% of [[duodenal]] [[ulcers]]) is chronic [[inflammation]] due to [[Helicobacter pylori]] that colonize the antral [[mucosa]]. The [[immune system]] is unable to clear the [[infection]], despite the appearance of [[antibodies]]. Thus, the [[bacterium]] can cause a [[Gastritis|chronic active gastritis]] (type B gastritis), resulting in a defect in the regulation of [[gastrin]] production and [[gastrin]] secretion is increased. [[Gastrin]] stimulates the production of [[gastric acid]] by [[Parietal cell|parietal cells]]. The [[acid]] erodes the [[mucosa]] and causes the [[ulcer]]. Another major cause is the use of [[NSAIDs]]  The [[gastric mucosa]] protects itself from [[gastric acid]] with a layer of [[mucus]], the secretion of which is stimulated by certain [[Prostaglandin|prostaglandins]]. [[NSAIDs]] block the function of cyclooxygenase 1 (cox-1), which is essential for the production of these [[Prostaglandin|prostaglandins]].
A major causative factor (60% of [[gastric]] and 90% of [[duodenal]] [[ulcers]]) is chronic [[inflammation]] due to [[Helicobacter pylori]] that colonize the antral [[mucosa]]. The [[immune system]] is unable to clear the [[infection]], despite the appearance of [[antibodies]]. Thus, the [[bacterium]] can cause a [[Gastritis|chronic active gastritis]] known as type B gastritis. This results in a defect in [[gastrin]] production leading to increased[[gastrin]] secretion. [[Gastrin]] stimulates the production of [[gastric acid]] by the [[Parietal cell|parietal cells]]. The [[acid]] erodes the [[mucosa]] and causes the [[ulcer]]. Another major cause of peptic ulcer disease is the chronic use of [[NSAIDs]]  The [[gastric mucosa]] protects itself from [[gastric acid]] with a layer of [[mucus]], the secretion of which is stimulated by certain [[Prostaglandin|prostaglandins]]. [[NSAIDs]] block the function of cyclooxygenase 1 (cox-1), which is essential for the production of these [[Prostaglandin|prostaglandins]].
 
==Pathophysiology==
==Pathophysiology==
[[Peptic ulcer]] occurs due to distruption of [[Muscularis mucosae|muscularis mucosa]] which occurs due to loss of defensive mechanism of [[gastric mucosa]]  
[[Peptic ulcer]] occurs due to distruption of [[Muscularis mucosae|muscularis mucosa]] which is required in the maintenance of the integrity of the [[gastric mucosa]]  


'''Defensive mechanism of gastric mucosa'''  
'''Defensive mechanism of gastric mucosa'''  


'''Mucosal barrier'''
Mucosal barrier consists of three protective components which include:<ref><nowiki>Butler BD, Lichtenberger LM |title=Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach |journal=Am. J. Physiol. |volume=244 |issue=5 |pages=G561–8 |year=1983 |pmid=6846549 |doi= |url=}}</nowiki></ref><ref name="pmid2657286">{{cite journal |vauthors=Clamp JR, Ene D |title=The gastric mucosal barrier |journal=Methods Find Exp Clin Pharmacol |volume=11 Suppl 1 |issue= |pages=19–25 |year=1989 |pmid=2657286 |doi= |url=}}</ref><ref name="pmid10677782">{{cite journal |vauthors=Werther JL |title=The gastric mucosal barrier |journal=Mt. Sinai J. Med. |volume=67 |issue=1 |pages=41–53 |year=2000 |pmid=10677782 |doi= |url=}}</ref><ref name="pmid3072665">{{cite journal |vauthors=Forssell H |title=Gastric mucosal defence mechanisms: a brief review |journal=Scand. J. Gastroenterol. Suppl. |volume=155 |issue= |pages=23–8 |year=1988 |pmid=3072665 |doi= |url=}}</ref>
*Mucosal barrier consists of three protective components which include:<ref><nowiki>Butler BD, Lichtenberger LM |title=Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach |journal=Am. J. Physiol. |volume=244 |issue=5 |pages=G561–8 |year=1983 |pmid=6846549 |doi= |url=}}</nowiki></ref><ref name="pmid2657286">{{cite journal |vauthors=Clamp JR, Ene D |title=The gastric mucosal barrier |journal=Methods Find Exp Clin Pharmacol |volume=11 Suppl 1 |issue= |pages=19–25 |year=1989 |pmid=2657286 |doi= |url=}}</ref><ref name="pmid10677782">{{cite journal |vauthors=Werther JL |title=The gastric mucosal barrier |journal=Mt. Sinai J. Med. |volume=67 |issue=1 |pages=41–53 |year=2000 |pmid=10677782 |doi= |url=}}</ref><ref name="pmid3072665">{{cite journal |vauthors=Forssell H |title=Gastric mucosal defence mechanisms: a brief review |journal=Scand. J. Gastroenterol. Suppl. |volume=155 |issue= |pages=23–8 |year=1988 |pmid=3072665 |doi= |url=}}</ref>
*Layer of [[Epithelial cells|epithelial cell lining]] which is bound by [[tight junctions]] that repel fluids
**Layer of [[Epithelial cells|epithelial cell lining]]:bound by [[tight junctions]] that repel fluids
*Layer of [[mucus]], secreted by surface [[epithelial cells]] and foveolar cells which forms a protective gel-like coating over the entire [[Gastric mucosal barrier|gastric mucosal surface]]  
**Layer of [[mucus]], secreted by surface [[epithelial cells]] and foveolar cells:Forms a protective gel-like coating over the entire [[Gastric mucosal barrier|gastric mucosal surface]]  
*Layer of [[Bicarbonate buffering system|bicarbonate ions]], secreted by the surface [[epithelial cells]] which [[Neutralization|neutralize acids]]
**Layer of [[Bicarbonate buffering system|bicarbonate ions]], secreted by the surface [[epithelial cells]]:[[Neutralization|Neutralize acids]]
[[Image: Stomach mucosal layer labeled.svg.png|center|frame|Diagram of alkaline Mucous layer in stomach with mucosal defense mechanisms<br> '''Source''':Wikimedia Commons <ref>By M•Komorniczak(http://creativecommons.org/licenses/by/3.0) </ref>]]
[[Image: Stomach mucosal layer labeled.svg.png|center|frame|Diagram of alkaline Mucous layer in stomach with mucosal defense mechanisms<br> '''Source''':Wikimedia Commons <ref>By M•Komorniczak(http://creativecommons.org/licenses/by/3.0) </ref>]]


Line 22: Line 20:
*[[Non-steroidal anti-inflammatory drug|Nonsteroidal anti-inflammatory drugs]] (NSAIDs)
*[[Non-steroidal anti-inflammatory drug|Nonsteroidal anti-inflammatory drugs]] (NSAIDs)
===Role of Helicobacter pylori===
===Role of Helicobacter pylori===
*[[Helicobacter pylori]] is gram-negative, spiral-shaped, motile , urease positive  [[bacteria]].
'''Penetration'''
*Factors help in penetration and growth of [[Helicobacter pylori]] are :<ref name="pmid16847081">{{cite journal |vauthors=Kusters JG, van Vliet AH, Kuipers EJ |title=Pathogenesis of Helicobacter pylori infection |journal=Clin. Microbiol. Rev. |volume=19 |issue=3 |pages=449–90 |year=2006 |pmid=16847081 |pmc=1539101 |doi=10.1128/CMR.00054-05 |url=}}</ref><ref name="pmid118091812">{{cite journal |vauthors=Huang JQ, Sridhar S, Hunt RH |title=Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis |journal=Lancet |volume=359 |issue=9300 |pages=14–22 |year=2002 |pmid=11809181 |doi=10.1016/S0140-6736(02)07273-2 |url=}}</ref>
 
** [[Bicarbonate]]-mediated chemotactic motility of  [[Helicobacter pylori]]   facilitates its penetration  
Factors that help in penetration and growth of [[Helicobacter pylori]] are:<ref name="pmid16847081">{{cite journal |vauthors=Kusters JG, van Vliet AH, Kuipers EJ |title=Pathogenesis of Helicobacter pylori infection |journal=Clin. Microbiol. Rev. |volume=19 |issue=3 |pages=449–90 |year=2006 |pmid=16847081 |pmc=1539101 |doi=10.1128/CMR.00054-05 |url=}}</ref><ref name="pmid118091812">{{cite journal |vauthors=Huang JQ, Sridhar S, Hunt RH |title=Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis |journal=Lancet |volume=359 |issue=9300 |pages=14–22 |year=2002 |pmid=11809181 |doi=10.1016/S0140-6736(02)07273-2 |url=}}</ref>
** Neutral pH favors the growth of [[helicobacter pylori]].
* [[Bicarbonate]]-mediated chemotactic motility of  [[Helicobacter pylori]] which facilitates its penetration  
* Neutral pH favors the growth of [[helicobacter pylori]]
'''Colonzation''':
*The colonization of virulent CagA-positive [[Helicobacter pylori]] strains leads to the degeneration of surface epithelial cells
*This degeneration results in increased exfoliation of surface epithelial cells
*The exfoliation mediated compensatory cell proliferation leads to the movement of immature cells to the foveolae and surface


*Immature cells leads to impaired mucin and bicarbonate production  and the integrity of the mucous barrier may be compromised
*All of above factors lead to activation of complement via the alternative pathway and the release of chemical mediators by mast cells and activated polymorphs may lead to microvascular disturbances and focal [[ischemic]] damage to the surface epithelium
*[[Helicobacter pylori]]  infection down-regulates E-cadherin expression in [[gastric]] epithelial cells which affect the resistance of the mucosa to acid attack
*Decreased mucus production, release of chemical mediators and down-regulation  of E- cadherin leads to [[mucosal]] damage leads to [[ulcer]] formation<ref name="pmid9930387">{{cite journal |vauthors=Kim JS, Jung HC, Kim JM, Song IS, Kim CY |title=Interleukin-8 expression by human neutrophils activated by Helicobacter pylori soluble proteins |journal=Scand. J. Gastroenterol. |volume=33 |issue=12 |pages=1249–55 |year=1998 |pmid=9930387 |doi= |url=}}</ref><ref name="pmid5077145">{{cite journal |vauthors=Kimura K |title=Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach |journal=Gastroenterology |volume=63 |issue=4 |pages=584–92 |year=1972 |pmid=5077145 |doi= |url=}}</ref><ref name="pmid10632311">{{cite journal |vauthors=Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL |title=Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? |journal=Arch. Intern. Med. |volume=160 |issue=1 |pages=105–9 |year=2000 |pmid=10632311 |doi= |url=}}</ref>
====Immunological response====
====Immunological response====
Factors responsible for immunological response of  [[Helicobacter pylori]] are :
Factors responsible for immunological response of  [[Helicobacter pylori]] are :
* [[Helicobacter pylori]]  [[infection]] triggers local production various [[proinflammatory]] mediators ([[cytokines]], [[neutrophil]] infiltration, specific T- and B- cells).
* [[Helicobacter pylori]]  [[infection]] triggers local production various [[proinflammatory]] mediators ([[cytokines]], [[neutrophil]] infiltration, specific T- and B- cells)


*Of all the [[cytotoxins]] and [[virulence factors]] Cag A, VacA, and OipA play a key role in the pathogenesis of  [[Helicobacter pylori]]  infection.
*Of all the [[cytotoxins]] and [[virulence factors]] Cag A, VacA, and OipA play a key role in the pathogenesis of  [[Helicobacter pylori]]  infection
*Cag A, VacA, and OipA not only  helps in the colonization of  [[Helicobacter pylori]]  but and also modulates host's immune system.
*Cag A, VacA, and OipA not only  helps in the colonization of  [[Helicobacter pylori]]  but and also modulates host's immune system
*[[Bacterial]] factors and [[complement]] activation leads to neutrophilic activation including reactive [[oxygen]],release of [[leukocytes]] [[enzymes]] and [[leukotriens]] lead to mucosal injury <ref>url=http://www.nejm.org/doi/full/10.1056/NEJM199003293221307<nowiki> |title=Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM |format= |work= |accessdate=}}</nowiki></ref> <ref name="pmid8730255">{{cite journal |vauthors=Logan RP |title=Adherence of Helicobacter pylori |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=3–15 |year=1996 |pmid=8730255 |doi= |url=}}</ref><ref name="pmid8730257">{{cite journal |vauthors=Crabtree JE |title=Gastric mucosal inflammatory responses to Helicobacter pylori |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=29–37 |year=1996 |pmid=8730257 |doi= |url=}}</ref><ref name="pmid7863238">{{cite journal |vauthors=Ernst PB, Jin Y, Reyes VE, Crowe SE |title=The role of the local immune response in the pathogenesis of peptic ulcer formation |journal=Scand. J. Gastroenterol. Suppl. |volume=205 |issue= |pages=22–8 |year=1994 |pmid=7863238 |doi= |url=}}</ref><ref name="urlPathogenesis of Peptic Ulcer and Implications for Therapy — NEJM"><nowiki>{{cite web </nowiki><nowiki><ref name="pmid16847081"></nowiki>{{cite journal |vauthors=Kusters JG, van Vliet AH, Kuipers EJ |title=Pathogenesis of Helicobacter pylori infection |journal=Clin. Microbiol. Rev. |volume=19 |issue=3 |pages=449–90 |year=2006 |pmid=16847081 |pmc=1539101 |doi=10.1128/CMR.00054-05 |url=}}</ref>
*[[Bacterial]] factors and [[complement]] activation leads to neutrophilic activation including reactive [[oxygen]],release of [[leukocytes]] [[enzymes]] and [[leukotriens]] lead to mucosal injury <ref>url=http://www.nejm.org/doi/full/10.1056/NEJM199003293221307<nowiki> |title=Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM |format= |work= |accessdate=}}</nowiki></ref> <ref name="pmid8730255">{{cite journal |vauthors=Logan RP |title=Adherence of Helicobacter pylori |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=3–15 |year=1996 |pmid=8730255 |doi= |url=}}</ref><ref name="pmid8730257">{{cite journal |vauthors=Crabtree JE |title=Gastric mucosal inflammatory responses to Helicobacter pylori |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=29–37 |year=1996 |pmid=8730257 |doi= |url=}}</ref><ref name="pmid7863238">{{cite journal |vauthors=Ernst PB, Jin Y, Reyes VE, Crowe SE |title=The role of the local immune response in the pathogenesis of peptic ulcer formation |journal=Scand. J. Gastroenterol. Suppl. |volume=205 |issue= |pages=22–8 |year=1994 |pmid=7863238 |doi= |url=}}</ref><ref name="urlPathogenesis of Peptic Ulcer and Implications for Therapy — NEJM"><nowiki>{{cite web </nowiki><nowiki><ref name="pmid16847081"></nowiki>{{cite journal |vauthors=Kusters JG, van Vliet AH, Kuipers EJ |title=Pathogenesis of Helicobacter pylori infection |journal=Clin. Microbiol. Rev. |volume=19 |issue=3 |pages=449–90 |year=2006 |pmid=16847081 |pmc=1539101 |doi=10.1128/CMR.00054-05 |url=}}</ref>
*[[Helicobacter pylori]]  secretes various enzyme :[[Urease]],[[Phospholipase|Phospholipases]],[[Alcohol dehydrogenase]] and Catalases- causes damage the host [[gastric]] muscosa by generating [[toxic]] metabolities<ref name="pmid8730260">{{cite journal |vauthors=Mobley HL |title=The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=57–64 |year=1996 |pmid=8730260 |doi= |url=}}</ref><ref name="pmid8730261">{{cite journal |vauthors=Nilius M, Malfertheiner P |title=Helicobacter pylori enzymes |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=65–71 |year=1996 |pmid=8730261 |doi= |url=}}</ref><ref name="pmid2801678">{{cite journal |vauthors=Slomiany BL, Kasinathan C, Slomiany A |title=Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol) |journal=Am. J. Gastroenterol. |volume=84 |issue=10 |pages=1273–7 |year=1989 |pmid=2801678 |doi= |url=}}</ref>
*[[Helicobacter pylori]]  secretes various enzyme :[[Urease]],[[Phospholipase|Phospholipases]],[[Alcohol dehydrogenase]] and Catalases- causes damage the host [[gastric]] muscosa by generating [[toxic]] metabolities<ref name="pmid8730260">{{cite journal |vauthors=Mobley HL |title=The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=57–64 |year=1996 |pmid=8730260 |doi= |url=}}</ref><ref name="pmid8730261">{{cite journal |vauthors=Nilius M, Malfertheiner P |title=Helicobacter pylori enzymes |journal=Aliment. Pharmacol. Ther. |volume=10 Suppl 1 |issue= |pages=65–71 |year=1996 |pmid=8730261 |doi= |url=}}</ref><ref name="pmid2801678">{{cite journal |vauthors=Slomiany BL, Kasinathan C, Slomiany A |title=Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol) |journal=Am. J. Gastroenterol. |volume=84 |issue=10 |pages=1273–7 |year=1989 |pmid=2801678 |doi= |url=}}</ref>


{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | | | A01 | | | | | |A01=Helicobacter pylori infection}}
{{familytree | | | | | | | | | A01 | | | | | |A01=[[Helicobacter pylori]] infection}}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | |B01 | | | | | B02 | | | | | B03 |B01=Inflammatory response<br>secretes IL-8 ,IL-1b|B02=Production of<br> alkaline ammonia |B03=Production of urease<br>bacterial phospholipase A}}
{{familytree | |B01 | | | | | B02 | | | | | B03 |B01=[[Inflammatory]] response<br>secretes IL-8 ,IL-1b|B02=Production of<br> alkaline [[ammonia]] |B03=Production of [[urease]]<br>[[bacterial]] phospholipase A}}
{{familytree | | |!| | | | | | |!| | | | | | |!| |}}
{{familytree | | |!| | | | | | |!| | | | | | |!| |}}
{{familytree | | C01 | | | | | C02 | | | | | C03 |C01=Infux of neutophils and macrophages<br>release of lysosomal enzymes<br>leukotrienes (LT)and<br>reactive oxygen |C02=inhibition of D-cells<br>leads to inappropriate release of somatostatin<br>and hypergastrinemia|C03=Production of urease<br>,phospholipase <br>A and C<br> release toxic metabolities}}
{{familytree | | C01 | | | | | C02 | | | | | C03 |C01=Infux of[[neutophils]]and[[macrophages]]<br>release of lysosomal enzymes<br>leukotrienes (LT)and<br>reactive oxygen |C02=Inhibition of D-cells<br>leads to inappropriate release of [[somatostatin]]<br>and [[hypergastrinemia]]|C03=Production of urease<br>,phospholipase <br>A and C<br> release toxic metabolities}}
{{familytree | | |!| | | | | | |!| | | | | | |!|}}
{{familytree | | |!| | | | | | |!| | | | | | |!|}}
{{familytree | | |`|-|-|-|-|-|-|+|-|-|-|-|-|-|'|}}
{{familytree | | |`|-|-|-|-|-|-|+|-|-|-|-|-|-|'|}}
{{familytree | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | D01 | | | | | |D01=Mucosal injury}}
{{familytree | | | | | | | | | D01 | | | | | |D01=[[Mucosal]] injury}}
{{Familytree/end}}
{{Familytree/end}}


'''Role of Helicobacter pylori in causing gastric ulcer'''
'''Role of Helicobacter pylori in causing gastric ulcer'''
* Colonzation:
*Factors responsible for [[ulcer]] formation:<ref name="pmid2263883">{{cite journal |vauthors=Sipponen P, Varis K, Fräki O, Korri UM, Seppälä K, Siurala M |title=Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients |journal=Scand. J. Gastroenterol. |volume=25 |issue=10 |pages=966–73 |year=1990 |pmid=2263883 |doi= |url=}}</ref>
**The colonization of virulent CagA-positive [[Helicobacter pylori]] strains leads to the degeneration of surface epithelial cells.
*There is decrease in acid and decrease in parietal cell volume which further predisposes to development to ulcer formation.<ref name="pmid10632311">{{cite journal |vauthors=Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL |title=Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? |journal=Arch. Intern. Med. |volume=160 |issue=1 |pages=105–9 |year=2000 |pmid=10632311 |doi= |url=}}</ref>
**This degeneration results in increased exfoliation of surface epithelial cells.
 
**The exfoliation mediated compensatory cell proliferation leads to the movement of immature cells to the foveolae and surface.
*Immature cells leads to impaired mucin and bicarbonate production  and the integrity of the mucous barrier may be compromised.
*All of above factors lead to activation of complement via the alternative pathway and the release of chemical mediators by mast cells and activated polymorphs may lead to microvascular disturbances and focal [[ischemic]] damage to the surface epithelium
*[[Helicobacter pylori]]  infection down-regulates E-cadherin expression in [[gastric]] epithelial cells which affect the resistance of the mucosa to acid attack
*Decreased mucus production, release of chemical mediators and down-regulation  of E- cadherin leads to [[mucosal]] damage leads to [[ulcer]] formation<ref name="pmid9930387">{{cite journal |vauthors=Kim JS, Jung HC, Kim JM, Song IS, Kim CY |title=Interleukin-8 expression by human neutrophils activated by Helicobacter pylori soluble proteins |journal=Scand. J. Gastroenterol. |volume=33 |issue=12 |pages=1249–55 |year=1998 |pmid=9930387 |doi= |url=}}</ref><ref name="pmid5077145">{{cite journal |vauthors=Kimura K |title=Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach |journal=Gastroenterology |volume=63 |issue=4 |pages=584–92 |year=1972 |pmid=5077145 |doi= |url=}}</ref><ref name="pmid10632311">{{cite journal |vauthors=Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL |title=Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? |journal=Arch. Intern. Med. |volume=160 |issue=1 |pages=105–9 |year=2000 |pmid=10632311 |doi= |url=}}</ref>
'''Role of Helicobacter pylori in causing duodenal ulcer'''
'''Role of Helicobacter pylori in causing duodenal ulcer'''
*Factors responsible for [[ulcer]] formation:
*Factors responsible for [[ulcer]] formation:
Line 81: Line 83:
{{familytree | | |`|-|-|-|-|-|-|+|-|-|-|-|-|-|'|}}
{{familytree | | |`|-|-|-|-|-|-|+|-|-|-|-|-|-|'|}}
{{familytree | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | D01 | | | | | |D01=Mucosal injury}}
{{familytree | | | | | | | | | D01 | | | | | | |D01=Mucosal injury}}
{{Familytree/end}}
{{Familytree/end}}


Line 99: Line 101:
**vacA
**vacA
==Associated Conditions==
==Associated Conditions==
*The  conditions associated with infection caused by helicobacter pylori include:<ref name="pmid25915048">{{cite journal |vauthors=Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC |title=Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis |journal=PLoS ONE |volume=10 |issue=4 |pages=e0124725 |year=2015 |pmid=25915048 |pmc=4411104 |doi=10.1371/journal.pone.0124725 |url=}}</ref><ref name="pmid25915048">{{cite journal |vauthors=Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC |title=Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis |journal=PLoS ONE |volume=10 |issue=4 |pages=e0124725 |year=2015 |pmid=25915048 |pmc=4411104 |doi=10.1371/journal.pone.0124725 |url=}}</ref><ref name="pmid21890816">{{cite journal |vauthors=Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M |title=Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan |journal=Gut |volume=61 |issue=4 |pages=507–13 |year=2012 |pmid=21890816 |doi=10.1136/gutjnl-2011-300495 |url=}}</ref><ref name="pmid15929755">{{cite journal |vauthors=Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, Shirai T, Mine T |title=Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial |journal=Am. J. Gastroenterol. |volume=100 |issue=6 |pages=1265–70 |year=2005 <ref name="pmid18945961">{{cite journal |vauthors=Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB |title=Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review |journal=Blood |volume=113 |issue=6 |pages=1231–40 |year=2009 |pmid=18945961 |doi=10.1182/blood-2008-07-167155 |url=}}</ref><ref name="pmid21325604">{{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |year=2011 |</ref><ref>name="urlAmerican Journal of Gastroenterology - ACG Clinical Guideline: Treatment of Helicobacter pylori Infection">{{cite web |url=https://www.nature.com/ajg/journal/v112/n2/full/ajg2016563a.html#bib31 |title=American Journal of Gastroenterology - ACG Clinical Guideline: Treatment of Helicobacter pylori Infection |format= |work= |accessdate=}}</ref>  
*The  conditions associated with infection caused by helicobacter pylori include:<ref name="pmid25915048">{{cite journal |vauthors=Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC |title=Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis |journal=PLoS ONE |volume=10 |issue=4 |pages=e0124725 |year=2015 |pmid=25915048 |pmc=4411104 |doi=10.1371/journal.pone.0124725 |url=}}</ref><ref name="pmid21890816">{{cite journal |vauthors=Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M |title=Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan |journal=Gut |volume=61 |issue=4 |pages=507–13 |year=2012 |pmid=21890816 |doi=10.1136/gutjnl-2011-300495 |url=}}</ref><ref name="pmid15929755">{{cite journal |vauthors=Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, Shirai T, Mine T |title=Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial |journal=Am. J. Gastroenterol. |volume=100 |issue=6 |pages=1265–70 |year=2005 <nowiki><ref name="pmid18945961"></nowiki>{{cite journal |vauthors=Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB |title=Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review |journal=Blood |volume=113 |issue=6 |pages=1231–40 |year=2009 |pmid=18945961 |doi=10.1182/blood-2008-07-167155 |url=}}</ref><ref name="pmid21325604"><nowiki>{{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |year=2011 |</nowiki></ref><ref>name="urlAmerican Journal of Gastroenterology - ACG Clinical Guideline: Treatment of Helicobacter pylori Infection">{{cite web |url=https://www.nature.com/ajg/journal/v112/n2/full/ajg2016563a.html#bib31 |title=American Journal of Gastroenterology - ACG Clinical Guideline: Treatment of Helicobacter pylori Infection |format= |work= |accessdate=}}</ref>  
**Gastric cancer
**[[Gastric cancer]]
**Gastric mucosa-associated lymphoid tissue (MALT) lymphoma
**Gastric mucosa-associated lymphoid tissue lymphoma ([[MALT]])  
**Idiopathic thrombocytopenic purpura
**[[Idiopathic thrombocytopenic purpura]]


==Gross Pathology==
==Gross Pathology==
*[[Gastric|Gastric ulcers]] are most often localized on the lesser curvature of the [[stomach]].
*[[Gastric|Gastric ulcers]] are most often localized on the lesser curvature of the [[stomach]]  
*[[Duodenal]] [[ulcers]] are more located at bulb of duodenum.
*[[Duodenal]] [[ulcers]] are more located at bulb of duodenum  
*Characteristic findings of a [[peptic ulcer]] on gross pathology include:
*Characteristic findings of a [[peptic ulcer]] on gross pathology include:
**Round to oval
**Round to oval
**2 to 4 cm diameter
**Two to four cm diameter
**Smooth base with perpendicular borders.
**Smooth base with perpendicular borders.
**Parietal scarring with radial folds may be evident in the surrounding mucosa.
**Parietal scarring with radial folds may be evident in the surrounding mucosa
<gallery widths="250px">
<gallery widths="250px">


Line 123: Line 125:


==Microscopic Pathology==
==Microscopic Pathology==
*A [[peptic ulcer]] is a mucosal defect produced by acid-pepsin aggression which penetrates the [[muscularis mucosae]] and muscularis propria.
*A [[peptic ulcer]] is a mucosal defect produced by acid-pepsin aggression which penetrates the [[muscularis mucosae]] and muscularis propria
*There is increased plasma cells, neutrophilic infiltrate, villous blunting
*There is increased plasma cells, neutrophilic infiltrate, villous blunting
*The surface epithelium usually shows mucous cell (pseudopyloric) metaplasia
*The surface epithelium usually shows mucous cell (pseudopyloric) metaplasia
*During the active phase, the base of the ulcer shows 4 zones:  
*During the active phase, the base of the ulcer shows 4 zones:  
**[[Inflammatory]] exudate: polymorphonuclear infiltration which along with bacterial products stimulate the production of IL 8 and tumor necrosis factor alpha (TNF-α) and IL-1 released by macrophages in response to bacterial [[lipopolysaccharide]]
**[[Inflammatory]] exudate: polymorphonuclear infiltration which along with bacterial products stimulate the production of IL-8 and tumor necrosis factor alpha (TNF-α) and IL-1 released by macrophages in response to bacterial [[lipopolysaccharide]]
**Fibrinoid necrosis
**Fibrinoid necrosis
**Granulation tissue  
**Granulation tissue  
**Fibrous tissue. The fibrous base of the ulcer may contain vessels with thickened wall or with thrombosis.<ref name="pathologyatlas">{{cite web | url=http://www.pathologyatlas.ro/Peptic%20ulcer.html| title=ATLAS OF PATHOLOGY|accessdate=2007-08-26}}</ref>
**Fibrous tissue. The fibrous base of the ulcer may contain vessels with thickened wall or with thrombosis<ref name="pathologyatlas">{{cite web | url=http://www.pathologyatlas.ro/Peptic%20ulcer.html| title=ATLAS OF PATHOLOGY|accessdate=2007-08-26}}</ref>


<gallery widths="250px">
<gallery widths="250px">
Line 141: Line 143:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />


[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Needs overview]]
[[Category:Needs overview]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Primary care]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Latest revision as of 23:37, 29 July 2020

Peptic ulcer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Peptic Ulcer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Upper GI Endoscopy

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic management
Surgical management

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

2017 ACG Guidelines for Peptic Ulcer Disease

Guidelines for the Indications to Test for, and to Treat, H. pylori Infection

Guidelines for First line Treatment Strategies of Peptic Ulcer Disease for Providers in North America

Guidlines for factors that predict the successful eradication when treating H. pylori infection

Guidelines to document H. pylori antimicrobial resistance in the North America

Guidelines for evaluation and testing of H. pylori antibiotic resistance

Guidelines for when to test for treatment success after H. pylori eradication therapy

Guidelines for penicillin allergy in patients with H. pylori infection

Guidelines for the salvage therapy

Peptic ulcer pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Peptic ulcer pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peptic ulcer pathophysiology

CDC on Peptic ulcer pathophysiology

Peptic ulcer pathophysiology in the news

Blogs on Peptic ulcer pathophysiology

to Hospitals Treating Peptic ulcer

Risk calculators and risk factors for Peptic ulcer pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

A major causative factor (60% of gastric and 90% of duodenal ulcers) is chronic inflammation due to Helicobacter pylori that colonize the antral mucosa. The immune system is unable to clear the infection, despite the appearance of antibodies. Thus, the bacterium can cause a chronic active gastritis known as type B gastritis. This results in a defect in gastrin production leading to increasedgastrin secretion. Gastrin stimulates the production of gastric acid by the parietal cells. The acid erodes the mucosa and causes the ulcer. Another major cause of peptic ulcer disease is the chronic use of NSAIDs The gastric mucosa protects itself from gastric acid with a layer of mucus, the secretion of which is stimulated by certain prostaglandins. NSAIDs block the function of cyclooxygenase 1 (cox-1), which is essential for the production of these prostaglandins.

Pathophysiology

Peptic ulcer occurs due to distruption of muscularis mucosa which is required in the maintenance of the integrity of the gastric mucosa

Defensive mechanism of gastric mucosa

Mucosal barrier consists of three protective components which include:[1][2][3][4]

Diagram of alkaline Mucous layer in stomach with mucosal defense mechanisms
Source:Wikimedia Commons [5]

The two most important etiological factors in the development of PUD are:[6][7][8]

Role of Helicobacter pylori

Penetration

Factors that help in penetration and growth of Helicobacter pylori are:[9][10]

Colonzation:

  • The colonization of virulent CagA-positive Helicobacter pylori strains leads to the degeneration of surface epithelial cells
  • This degeneration results in increased exfoliation of surface epithelial cells
  • The exfoliation mediated compensatory cell proliferation leads to the movement of immature cells to the foveolae and surface
  • Immature cells leads to impaired mucin and bicarbonate production and the integrity of the mucous barrier may be compromised
  • All of above factors lead to activation of complement via the alternative pathway and the release of chemical mediators by mast cells and activated polymorphs may lead to microvascular disturbances and focal ischemic damage to the surface epithelium
  • Helicobacter pylori infection down-regulates E-cadherin expression in gastric epithelial cells which affect the resistance of the mucosa to acid attack
  • Decreased mucus production, release of chemical mediators and down-regulation of E- cadherin leads to mucosal damage leads to ulcer formation[11][12][13]

Immunological response

Factors responsible for immunological response of Helicobacter pylori are :

 
 
 
 
 
 
 
 
Helicobacter pylori infection
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory response
secretes IL-8 ,IL-1b
 
 
 
 
Production of
alkaline ammonia
 
 
 
 
Production of urease
bacterial phospholipase A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infux ofneutophilsandmacrophages
release of lysosomal enzymes
leukotrienes (LT)and
reactive oxygen
 
 
 
 
Inhibition of D-cells
leads to inappropriate release of somatostatin
and hypergastrinemia
 
 
 
 
Production of urease
,phospholipase
A and C
release toxic metabolities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mucosal injury
 
 
 
 
 

Role of Helicobacter pylori in causing gastric ulcer

  • Factors responsible for ulcer formation:[21]
  • There is decrease in acid and decrease in parietal cell volume which further predisposes to development to ulcer formation.[13]

Role of Helicobacter pylori in causing duodenal ulcer

Role of NSAIDS

 
 
 
 
 
 
 
 
NSAIDs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COX-1 inhibitor
 
 
 
 
Topical irritation
 
 
 
 
COX-2 inhibitor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Decreased blood flow
 
 
 
 
Epithelial damage
 
 
 
 
Inhibit
leucocyte adhesion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mucosal injury
 
 
 
 
 
 

Other factors

Other factors responsible for peptic ulcer disease:

Smoking

  • Chronic smoking leads to mucosal damage or deals healing of ulcer by following mechanism:[30]

Severe stress

Genetics

Associated Conditions

Gross Pathology

  • Gastric ulcers are most often localized on the lesser curvature of the stomach
  • Duodenal ulcers are more located at bulb of duodenum
  • Characteristic findings of a peptic ulcer on gross pathology include:
    • Round to oval
    • Two to four cm diameter
    • Smooth base with perpendicular borders.
    • Parietal scarring with radial folds may be evident in the surrounding mucosa

Microscopic Pathology

  • A peptic ulcer is a mucosal defect produced by acid-pepsin aggression which penetrates the muscularis mucosae and muscularis propria
  • There is increased plasma cells, neutrophilic infiltrate, villous blunting
  • The surface epithelium usually shows mucous cell (pseudopyloric) metaplasia
  • During the active phase, the base of the ulcer shows 4 zones:
    • Inflammatory exudate: polymorphonuclear infiltration which along with bacterial products stimulate the production of IL-8 and tumor necrosis factor alpha (TNF-α) and IL-1 released by macrophages in response to bacterial lipopolysaccharide
    • Fibrinoid necrosis
    • Granulation tissue
    • Fibrous tissue. The fibrous base of the ulcer may contain vessels with thickened wall or with thrombosis[38]

References

  1. ↑ Butler BD, Lichtenberger LM |title=Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach |journal=Am. J. Physiol. |volume=244 |issue=5 |pages=G561–8 |year=1983 |pmid=6846549 |doi= |url=}}
  2. ↑ Clamp JR, Ene D (1989). "The gastric mucosal barrier". Methods Find Exp Clin Pharmacol. 11 Suppl 1: 19–25. PMID 2657286.
  3. ↑ Werther JL (2000). "The gastric mucosal barrier". Mt. Sinai J. Med. 67 (1): 41–53. PMID 10677782.
  4. ↑ Forssell H (1988). "Gastric mucosal defence mechanisms: a brief review". Scand. J. Gastroenterol. Suppl. 155: 23–8. PMID 3072665.
  5. ↑ By M•Komorniczak(http://creativecommons.org/licenses/by/3.0)
  6. ↑ url=http://www.nejm.org/doi/full/10.1056/NEJM199003293221307 |title=Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM |format= |work= |accessdate=}}
  7. ↑ 7.0 7.1 "Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM".
  8. ↑ Hawkey CJ (1999). "Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance". Aliment. Pharmacol. Ther. 13 (6): 695–702. PMID 10383497.
  9. ↑ Kusters JG, van Vliet AH, Kuipers EJ (2006). "Pathogenesis of Helicobacter pylori infection". Clin. Microbiol. Rev. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC 1539101. PMID 16847081.
  10. ↑ Huang JQ, Sridhar S, Hunt RH (2002). "Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis". Lancet. 359 (9300): 14–22. doi:10.1016/S0140-6736(02)07273-2. PMID 11809181.
  11. ↑ Kim JS, Jung HC, Kim JM, Song IS, Kim CY (1998). "Interleukin-8 expression by human neutrophils activated by Helicobacter pylori soluble proteins". Scand. J. Gastroenterol. 33 (12): 1249–55. PMID 9930387.
  12. ↑ Kimura K (1972). "Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach". Gastroenterology. 63 (4): 584–92. PMID 5077145.
  13. ↑ 13.0 13.1 Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL (2000). "Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection?". Arch. Intern. Med. 160 (1): 105–9. PMID 10632311.
  14. ↑ url=http://www.nejm.org/doi/full/10.1056/NEJM199003293221307 |title=Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM |format= |work= |accessdate=}}
  15. ↑ Logan RP (1996). "Adherence of Helicobacter pylori". Aliment. Pharmacol. Ther. 10 Suppl 1: 3–15. PMID 8730255.
  16. ↑ Crabtree JE (1996). "Gastric mucosal inflammatory responses to Helicobacter pylori". Aliment. Pharmacol. Ther. 10 Suppl 1: 29–37. PMID 8730257.
  17. ↑ Ernst PB, Jin Y, Reyes VE, Crowe SE (1994). "The role of the local immune response in the pathogenesis of peptic ulcer formation". Scand. J. Gastroenterol. Suppl. 205: 22–8. PMID 7863238.
  18. ↑ Mobley HL (1996). "The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration". Aliment. Pharmacol. Ther. 10 Suppl 1: 57–64. PMID 8730260.
  19. ↑ Nilius M, Malfertheiner P (1996). "Helicobacter pylori enzymes". Aliment. Pharmacol. Ther. 10 Suppl 1: 65–71. PMID 8730261.
  20. ↑ Slomiany BL, Kasinathan C, Slomiany A (1989). "Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol)". Am. J. Gastroenterol. 84 (10): 1273–7. PMID 2801678.
  21. ↑ Sipponen P, Varis K, Fräki O, Korri UM, Seppälä K, Siurala M (1990). "Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients". Scand. J. Gastroenterol. 25 (10): 966–73. PMID 2263883.
  22. ↑ Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV (1987). "Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis". J. Clin. Pathol. 40 (8): 841–8. PMC 1141122. PMID 3654985.
  23. ↑ el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE (1995). "Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease". Gastroenterology. 109 (3): 681–91. PMID 7657096.
  24. ↑ el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE (1993). "Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer". Gut. 34 (8): 1060–5. PMC 1374354. PMID 8174954.
  25. ↑ el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE (1995). "Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease". Gastroenterology. 109 (3): 681–91. PMID 7657096.
  26. ↑ el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE (1993). "Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer". Gut. 34 (8): 1060–5. PMC 1374354. PMID 8174954.
  27. ↑ Borody TJ, George LL, Brandl S, Andrews P, Ostapowicz N, Hyland L, Devine M (1991). "Helicobacter pylori-negative duodenal ulcer". Am. J. Gastroenterol. 86 (9): 1154–7. PMID 1882793.
  28. ↑ Huang JQ, Sridhar S, Hunt RH (2002). "Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis". Lancet. 359 (9300): 14–22. doi:10.1016/S0140-6736(02)07273-2. PMID 11809181.
  29. ↑ Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML (1991). "Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study". Gut. 32 (7): 730–4. PMC 1378985. PMID 1855677.
  30. ↑ Müller-Lissner SA (1986). "Bile reflux is increased in cigarette smokers". Gastroenterology. 90 (5 Pt 1): 1205–9. PMID 3956939.
  31. ↑ Räihä I, Kemppainen H, Kaprio J, Koskenvuo M, Sourander L (1998). "Lifestyle, stress, and genes in peptic ulcer disease: a nationwide twin cohort study". Arch. Intern. Med. 158 (7): 698–704. PMID 9554675.
  32. ↑ FakhreYaseri H, Shakaraby M, Bradaran HR, Soltani Arabshahi SK, Fakhre Yaseri AM (2014). "CagA and VacA genotypes in peptic ulcer disease and non-ulcer dyspepsia: a case-control study". Med J Islam Repub Iran. 28: 104. PMC 4301206. PMID 25664305.
  33. ↑ Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC (2015). "Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis". PLoS ONE. 10 (4): e0124725. doi:10.1371/journal.pone.0124725. PMC 4411104. PMID 25915048.
  34. ↑ Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M (2012). "Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan". Gut. 61 (4): 507–13. doi:10.1136/gutjnl-2011-300495. PMID 21890816.
  35. ↑ {{cite journal |vauthors=Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, Shirai T, Mine T |title=Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial |journal=Am. J. Gastroenterol. |volume=100 |issue=6 |pages=1265–70 |year=2005 <ref name="pmid18945961">Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB (2009). "Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review". Blood. 113 (6): 1231–40. doi:10.1182/blood-2008-07-167155. PMID 18945961.
  36. ↑ {{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |year=2011 |
  37. ↑ name="urlAmerican Journal of Gastroenterology - ACG Clinical Guideline: Treatment of Helicobacter pylori Infection">"American Journal of Gastroenterology - ACG Clinical Guideline: Treatment of Helicobacter pylori Infection".
  38. ↑ "ATLAS OF PATHOLOGY". Retrieved 2007-08-26.

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Peptic_ulcer_pathophysiology&oldid=1641957"